Search hospitals > Kansas > Mission
University of Kansas Clinical Research Center
Claim this profileMission, Kansas 66205
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Leukemia
Conducts research for Acute Myeloid Leukemia
Conducts research for Lymphoma
152 reported clinical trials
45 medical researchers
Summary
University of Kansas Clinical Research Center is a medical facility located in Mission, Kansas. This center is recognized for care of Cancer, Tumors, Leukemia, Acute Myeloid Leukemia, Lymphoma and other specialties. University of Kansas Clinical Research Center is involved with conducting 152 clinical trials across 554 conditions. There are 45 research doctors associated with this hospital, such as Jun Zhang, Gary C. Doolittle, Chao H. Huang, and Jeffrey Statland.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Tumors
Global LeaderStage IV
Stage III
HER2 positive
Top PIs
Jun ZhangHouston Methodist Hospital4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
25 reported clinical trials
40 drugs studied
Gary C. DoolittleHaysMed University of Kansas Health System3 years of reported clinical research
Studies Cancer
Studies Melanoma
18 reported clinical trials
29 drugs studied
Chao H. HuangUniversity of Kansas Health System Saint Francis Campus5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
19 reported clinical trials
31 drugs studied
Jeffrey StatlandUniversity of Kansas Medical Center1 year of reported clinical research
Studies Muscular Dystrophy
Studies Duchenne Muscular Dystrophy
19 reported clinical trials
19 drugs studied
Clinical Trials running at University of Kansas Clinical Research Center
Acute Myeloid Leukemia
Cancer
Prostate Cancer
Bladder Carcinoma
Squamous Cell Carcinoma
Non-Hodgkin's Lymphoma
Pancreatic Cancer
Leukemia
Myelodysplastic Syndrome
Renal Cell Carcinoma
CYAD-02
for Leukemia/Preleukemia
This trial tests CYAD-02, a cell-based treatment, in patients with relapsed or refractory AML or MDS who haven't responded to standard treatments. Patients receive mild chemotherapy first, followed by CYAD-02 infusions to target cancer cells. If effective, they may receive additional doses.
Recruiting3 awards Phase 16 criteria
Screening Tool
for Myeloid Cancer
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Recruiting1 award Phase 21 criteria
Novel Therapies
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.
Recruiting1 award Phase 217 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Kansas Clinical Research Center?
University of Kansas Clinical Research Center is a medical facility located in Mission, Kansas. This center is recognized for care of Cancer, Tumors, Leukemia, Acute Myeloid Leukemia, Lymphoma and other specialties. University of Kansas Clinical Research Center is involved with conducting 152 clinical trials across 554 conditions. There are 45 research doctors associated with this hospital, such as Jun Zhang, Gary C. Doolittle, Chao H. Huang, and Jeffrey Statland.